Dermabacs®

30 Kapseln pro Packung, Einnahmemenge für 30 Tage

Nur die probiotischen Bakterienstämme, die in den meisten Studien untersucht wurden und die beste Wirksamkeit gezeigt haben, sind in unseren Synbiotika enthalten.

11 Bakterienstämme - 40 Milliarden koloniebildende Einheiten (KBEs):

• Bifidobacterium breve BR03
• Lactobacillus salivarius LS03
• Lactobacillus rhamnosus LR05
• Lactobacillus salivarius LS01
• Lactobacillus casei LC03
• Lactobacillus delbrueckii subsp. bulgaricus LDB01
• Bifidobacterium animalis subsp. lactis BS01
• Lactobacillus rhamnosus GG
• Bifidobacterium lactis BPL1 CECT 8145
• Bifidobacterium longum ES1 CECT 7347
• Lactobacillus casei BPL4 CECT 9104 

Andere Zutaten:

• 13% Inulin aus Chicoréewurzelpulver
• Hydroxypropylmethylcellulose (veg. Kapselhülle)
• Trennmittel: Magnesiumsalze von Speisefettsäuren
• Zinkgluconat 5mg
• Modifizierte Maisstärke
• Maltodextrin
• Farbstoff Calciumcarbonat (Kapselhülle)

Die Einnahme erfolgt täglich, idealerweise auf nüchternen Magen in der Früh.

Eine Kapsel ca. 30 Minuten vor dem Frühstück mit einem Glas Wasser einnehmen oder den Kapselinhalt bei Schwierigkeiten beim Schlucken in Wasser oder Joghurt einrühren.

• Zink trägt dazu bei, Zellen vor oxidativem Stress zu schützen (Verordnung (EU) Nr. 432/2012).
• Zink trägt zur Erhaltung normaler Haut bei (Verordnung (EU) Nr. 432/2012).
• Zink trägt zur Erhaltung normaler Haut und Nägel bei (Verordnung (EU) Nr. 432/2012).

Studien

• https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850513/https://www.researchgate.net/publication/265964661_Probiotics_as_a_Novel_Adjuvant_Approach_to_Atopic_Dermatitis
• https://pubmed.ncbi.nlm.nih.gov/27087407/
• https://pubmed.ncbi.nlm.nih.gov/25291127/
• https://pubmed.ncbi.nlm.nih.gov/23582165/
• https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3446166/
• https://www.researchgate.net/publication/265964661_Probiotics_as_a_Novel_Adjuvant_Approach_to_Atopic_Dermatitis

Acne

Deidda, F., Amoruso, A., Nicola, S., Graziano, T., Pane, M., & Mogna, L. (2018). New Approach in Acne Therapy: A Specific Bacteriocin Activity and a Targeted Anti IL-8 Property in Just 1 Probiotic Strain, the: L. salivarius: LS03. Journal of clinical gastroenterology, 52, S78-S81.

Bowe, W. P., Filip, J. C., DiRienzo, J. M., Volgina, A., & Margolis, D. J. (2006). Inhibition of propionibacterium acnes by bacteriocin-like inhibitory substances (BLIS) produced by Streptococcus salivarius. Journal of drugs in dermatology : JDD, 5(9), 868–870.

Rinaldi, F., Marotta, L., Mascolo, A., Amoruso, A., Pane, M., Giuliani, G., & Pinto, D. (2022). Facial Acne: A Randomized, Double-Blind, Placebo-Controlled Study on the Clinical Efficacy of a Symbiotic Dietary Supplement. Dermatology and therapy, 12(2), 577–589.

Jung, G. W., Tse, J. E., Guiha, I., & Rao, J. (2013). Prospective, randomized, open-label trial comparing the safety, efficacy, and tolerability of an acne treatment regimen with and without a probiotic supplement and minocycline in subjects with mild to moderate acne. Journal of cutaneous medicine and surgery, 17(2), 114–122.

Kim, J., Ko, Y., Park, Y. K., Kim, N. I., Ha, W. K., & Cho, Y. (2010). Dietary effect of lactoferrin-enriched fermented milk on skin surface lipid and clinical improvement of acne vulgaris. Nutrition (Burbank, Los Angeles County, Calif.), 26(9), 902–909

Yee, B. E., Richards, P., Sui, J. Y., & Marsch, A. F. (2020). Serum zinc levels and efficacy of zinc treatment in acne vulgaris: A systematic review and meta‐analysis. Dermatologic therapy, 33(6), e14252.

Cervantes J, Eber AE, Perper M, Nascimento VM, Nouri K, Keri JE. The role of zinc in the treatment of acne: A review of the literature. Dermatol Ther. 2018 Jan;31(1).

 
Rosacea

Fortuna, M. C., Garelli, V., Pranteda, G., Romaniello, F., Cardone, M., Carlesimo, M., & Rossi, A. (2016). A case of Scalp Rosacea treated with low dose doxycycline and probiotic therapy and literature review on therapeutic options. Dermatologic therapy, 29(4), 249–251.

Sharquie KE, Najim RA, Al-Salman HN. Oral zinc sulfate in the treatment of rosacea: a double-blind, placebo-controlled study. Int J Dermatol. 2006 Jul;45(7):857-61               

Atopic Dermatitis

Manzotti, G., Fassio, F., & Heffler, E. (2014). Probiotics as a Novel Adjuvant Approach to Atopic Dermatitis. JOURNAL OF CONTEMPORARY IMMUNOLOGY, 1(2), 57-66.29(4), 249–251

Drago, L., De Vecchi, E., Toscano, M., Vassena, C., Altomare, G., & Pigatto, P. (2014). Treatment of atopic dermatitis eczema with a high concentration of Lactobacillus salivarius LS01 associated with an innovative gelling complex: a pilot study on adults. Journal of clinical gastroenterology, 48 Suppl 1, S47–S51.

Farid, R., Ahanchian, H., Jabbari, F., & Moghiman, T. (2011). Effect of a new synbiotic mixture on atopic dermatitis in children: a randomized-controlled trial. Iranian journal of pediatrics, 21(2), 225–230.

Navarro-López V, Ramírez-Boscá A, Ramón-Vidal D, et al. Effect of Oral Administration of a Mixture of Probiotic Strains on SCORAD Index and Use of Topical Steroids in Young Patients With Moderate Atopic Dermatitis: A Randomized Clinical Trial. JAMA Dermatol. 2018;154(1):37-43.

Climent E, Martinez-Blanch JF, Llobregat L, Ruzafa-Costas B, Carrión-Gutiérrez MÁ, Ramírez-Boscá A, Prieto-Merino D, Genovés S, Codoñer FM, Ramón D, Chenoll E, Navarro-López V. Changes in Gut Microbiota Correlates with Response to Treatment with Probiotics in Patients with Atopic Dermatitis. A Post Hoc Analysis of a Clinical Trial. Microorganisms. 2021 Apr 15;9(4):854

Mohammedsaeed, W., McBain, A. J., Cruickshank, S. M., & O'Neill, C. A. (2014). Lactobacillus rhamnosus GG inhibits the toxic effects of Staphylococcus aureus on epidermal keratinocytes. Applied and environmental microbiology, 80(18), 5773–5781.